$ILMN News

Illumina Q2 Earnings Call Highlights

ILMN Q2 Deep Dive: Clinical Strength, Platform Expansion, and Strategic Focus Drive Guidance Lift

Illumina CEO on Genomic Sequencing Opportunities and AI

RBC Capital Maintains Outperform on Illumina, Raises Price Target to $230

Illumina, Inc. 2026 Q2 - Results - Earnings Call Presentation

JP Morgan Maintains Overweight on Illumina, Raises Price Target to $230

TD Cowen Maintains Hold on Illumina, Raises Price Target to $210

Illumina, Inc. Q2 2026 Earnings Call Summary

Guggenheim Maintains Buy on Illumina, Raises Price Target to $226

Stifel Maintains Buy on Illumina, Raises Price Target to $225

Barclays Maintains Underweight on Illumina, Raises Price Target to $160

Illumina Inc (ILMN) (Q2 2026) Earnings Call Highlights: Strong Clinical Growth Drives Revenue ...

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Illumina (NASDAQ:ILMN) Beats Q2 Estimates but Shares Slide 6% After-Hours

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript

Illumina Raises FY2026 Adj EPS Guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 Est; Raises FY2026 Sales Guidance from $4.520B-$4.620B to $4.600B-$4.640B vs $4.566B Est